Re: Farmas USA
El último research de FBR es de enero:
January 18, 2017 7:34 AM EST
FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Novavax (NASDAQ: NVAX) after meeting with management and hearing about development plans for 2017.
The analyst is focused on the small safety study using revised RSV vaccine dosing regimens that is planned for initiation later in 1Q17 (estimated top-line data in 3Q17) as one that will confirm the
vaccine’s path toward possible regulatory approval. The value of the Phase III maternal RSV vaccine remains largely under-recognized for its potential to be a catalyst for the stock (estimated top-line data in late 4Q17). With the identification of a Zika virus (ZIKV) preclinical vaccine candidate, the analyst thinks NVAX could emerge as a leading developer of a ZIKV vaccine in 2H17. Price target of $12.00